Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study

Tekijä Furie, Richard A, Mitrane, Margaret, Zhao, Enxu, Becker, Patrice M
Julkaisussa Lupus Sci Med (2017)

β(2)-glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model

Tekijä Arad, Ariela, Proulle, Valerie, Furie, Richard A., Furie, Barbara C., Furie, Bruce
Julkaistu 2011

Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Tekijä Askanase, Anca D., Zhao, Enxu, Zhu, Julie, Bilyk, Roman, Furie, Richard A.
Julkaisussa Rheumatol Ther (2020)

Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS

Tekijä Proulle, Valerie, Furie, Richard A., Merrill-Skoloff, Glenn, Furie, Barbara C., Furie, Bruce
Julkaistu 2014

Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-control...

Tekijä Askanase, Anca D, Zhao, Enxu, Zhu, Julie, Connolly-Strong, Erin, Furie, Richard A
Julkaisussa Lupus Sci Med (2020)

Diversification of the Ig Variable Region Gene Repertoire of Synovial B Lymphocytes by Nucleotide Insertion and Deletion

Tekijä Miura, Yasushi, Chu, Charles C, Dines, David M, Asnis, Stanley E, Furie, Richard A, Chiorazzi, Nicholas
Julkaistu 2003

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

Tekijä Tummala, Raj, Abreu, Gabriel, Pineda, Lilia, Michaels, M Alex, Kalyani, Rubana N, Furie, Richard A, Morand, Eric F
Julkaisussa Lupus Sci Med (2021)

Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar(®) Gel) for Persistently Act...

Tekijä Askanase, Anca D., Wan, George J., Panaccio, Mary P., Zhao, Enxu, Zhu, Julie, Bilyk, Roman, Furie, Richard A.
Julkaisussa Rheumatol Ther (2021)

Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy‐Six–Week Phase III Parent Study in the United States

Tekijä Furie, Richard A., Wallace, Daniel J., Aranow, Cynthia, Fettiplace, James, Wilson, Barbara, Mistry, Prafull, Roth, David A., Gordon, David
Julkaisussa Arthritis Rheumatol (2018)

Clonal expansion is a characteristic feature of the B-cell repertoire of patients with rheumatoid arthritis

Tekijä Itoh, Kenji, Patki, Varsha, Furie, Richard A, Chartash, Elliot K, Jain, Rita I, Lane, Lewis, Asnis, Stanley E, Chiorazzi, Nicholas
Julkaistu 2000

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE

Tekijä Merrill, Joan T, Petri, Michelle A, Buyon, Jill, Ramsey-Goldman, Rosalind, Kalunian, Kenneth, Putterman, Chaim, Conklin, John, Furie, Richard A, Dervieux, Thierry
Julkaisussa Lupus Sci Med (2018)

Immunoglobulin Heavy Chain Variable Region Gene Replacement as a Mechanism for Receptor Revision in Rheumatoid Arthritis Synovial Tissue B Lymphocytes

Tekijä Itoh, Kenji, Meffre, Eric, Albesiano, Emilia, Farber, Andrew, Dines, David, Stein, Peter, Asnis, Stanley E., Furie, Richard A., Jain, Rita I., Chiorazzi, Nicholas
Julkaistu 2000

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lu...

Tekijä Teng, Y K Onno, Bruce, Ian N, Diamond, Betty, Furie, Richard A, van Vollenhoven, Ronald F, Gordon, David, Groark, James, Henderson, Robert B, Oldham, Mary, Tak, Paul P
Julkaisussa BMJ Open (2019)

Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study

Tekijä van Vollenhoven, Ronald F, Stohl, William, Furie, Richard A, Fox, Norma Lynn, Groark, James G, Bass, Damon, Kurtinecz, Milena, Pobiner, Bonnie F, Eastman, William J, Gonzalez‑Rivera, Tania, Gordon, David
Julkaisussa Lupus Sci Med (2018)

Novel Evidence-Based Systemic Lupus Erythematosus Responder Index

Tekijä Furie, Richard A., Petri, Michelle A., Wallace, Daniel J., Ginzler, Ellen M., Merrill, Joan T., Stohl, William, Chatham, W. Winn, Strand, Vibeke, Weinstein, Arthur, Chevrier, Marc R., Zhong, John, Freimuth, William W.
Julkaistu 2009

Clinical response to belimumab in academic clinical practices

Tekijä Reddy, Arthi, Li, XiaoQing, Buyon, Jill P, Franks, Andrew G, Furie, Richard A, Kamen, Diane L, Manzi, Susan, Petri, Michelle, Ramsey-Goldman, Rosalind, Tseng, Chung-E, van Vollenhoven, Ronald F, Wallace, Daniel J, Askanase, Anca D
Julkaistu 2014

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus

Tekijä Wallace, Daniel J., Ginzler, Ellen M., Merrill, Joan T., Furie, Richard A., Stohl, William, Chatham, W. Winn, Weinstein, Arthur, McKay, James D., McCune, W. Joseph, Petri, Michelle, Fettiplace, James, Roth, David A., Ji, Beulah, Heath, Amy
Julkaisussa Arthritis Rheumatol (2019)

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus

Tekijä Wallace, Daniel J., Stohl, William, Furie, Richard A., Lisse, Jeffrey R., McKay, James D., Merrill, Joan T., Petri, Michelle A., Ginzler, Ellen M., Chatham, W. Winn, McCune, W. Joseph, Fernandez, Vivian, Chevrier, Marc R., Zhong, John, Freimuth, William W.
Julkaistu 2009

Safety and efficacy of belimumab in systemic lupus erythematosus academic clinical practices

Tekijä Hui-Yuen, Joyce S., Reddy, Arthi, Taylor, Jennifer, Li, Xiaoqing, Eichenfield, Andrew H., Bermudez, Liza M., Starr, Amy J., Imundo, Lisa F., Buyon, Jill, Furie, Richard A., Kamen, Diane L., Manzi, Susan, Petri, Michelle, Ramsey-Goldman, Rosalind, van Vollenhoven, Ronald F., Wallace, Daniel J., Askanase, Anca
Julkaisussa J Rheumatol (2015)

Cell-bound complement activation products associate with lupus severity in SLE

Tekijä Arriens, Cristina, Alexander, Roberta Vezza, Narain, Sonali, Saxena, Amit, Collins, Christopher E, Wallace, Daniel J, Massarotti, Elena, Conklin, John, Kalunian, Kenneth C, Putterman, Chaim, Ramsey-Goldman, Rosalind, Buyon, Jill P, Askanase, Anca, Furie, Richard A, James, Judith A, Bello, Ghalib A, Manzi, Susan, Ahearn, Joseph, O'Malley, Tyler, Weinstein, Arthur, Dervieux, Thierry
Julkaisussa Lupus Sci Med (2020)